Format

Send to

Choose Destination
See comment in PubMed Commons below
Diabetes Technol Ther. 2013 Apr;15(4):342-3. doi: 10.1089/dia.2012.0328. Epub 2013 Feb 4.

Liraglutide effective in the severely insulin-resistant patient with type 2 diabetes requiring U-500 insulin: a case report.

Author information

1
Department of Endocrinology, Cleveland Clinic, Cleveland, Ohio 44195, USA. pantalk@ccf.org

Abstract

BACKGROUND/OBJECTIVE:

We describe the effectiveness of liraglutide therapy in a severely insulin-resistant patient with type 2 diabetes mellitus (DM-2) requiring U-500 insulin.

SUBJECT AND METHODS:

A 65-year-old morbidly obese man (body mass index, 67.3 kg/m(2); weight, 156.2 kg) presented with a 20-year history of DM-2; the glycemic control deteriorated to U-500 insulin requirement. He was inadequately controlled (hemoglobin A1c [HbA1c], 9.1%) on metformin plus U-500 insulin titrated to 575 units daily. Liraglutide was added and titrated to 1.8 mg once daily over 3 weeks.

RESULTS:

Insulin requirements decreased markedly (>50%) to 250 units daily after 5 months of added liraglutide, with a concurrent improvement in HbA1c from 9.1% to 6.9% and weight loss of 22.6 kg.

CONCLUSIONS:

The addition of once-daily liraglutide to the regimen of patients with uncontrolled DM-2 requiring U-500 insulin should be considered as it may help to reduce insulin requirements, improve glycemic control, and assist with weight management.

PMID:
23379638
DOI:
10.1089/dia.2012.0328
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Mary Ann Liebert, Inc.
    Loading ...
    Support Center